Enrich Biosystems is developing novel high-throughput, microfluidics-free cell discovery platforms that addresses critical gaps in existing technologies. Our technology enables more confident screening, isolation and discovery of cell therapy candidates, quick, easy and robust sample processing for single-cell omics analyses, and flexible cell line purification workflows. We are located in Branford, CT.
Jay is an electrical engineer, serial entrepreneur, and now an investor and advisor to promising young companies primarily in life science instrumentation.
As Founder and CEO of Seahorse Bioscience, he and his team enabled scientists to visualize metabolic activity in living cells, creating new discoveries, a new market, and high growth leading to a sale to Agilent in 2016.
While investor and Director of Axion Bioscience, the company enabled a new field of study of electrical interactions among living cells and created a valuable business sold to Summa Equity in 2021.
Working with private equity firm Artemis Capital Partners, Jay supported the sale, growth and high-value re-sale of BioDot Inc, a leader in nanoliter scale liquid transfer systems for medical diagnostics in 2021.
In Jay’s first CEO role, he led a private equity buyout, rapid growth and high-value sale of Inframetrics Inc, manufacturer of high-performance thermal imaging systems for defense, industrial and life science applications.
Since engaging with Enrich in 2020, Jay has used his experience to help with strategy, fundraising, and KOL development.
Throughout his career, Christopher McLeod has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. Currently, Mr. McLeod is a managing partner at Elm Street Ventures, where he nurtures new ventures as an investor and advisor. He is a corporate director of three early stage companies.
In 2012, Mr. McLeod co-founded AxioMx, Inc., serving as President and CEO. AxioMx created technology to quickly develop custom antibodies for use in research and diagnostics. AxioMx was acquired by Abcam, plc in 2015.
Mr. McLeod served as President and Chief Executive Officer of 454 Life Sciences from February 2005 through September 2011, where he led the development, manufacturing and marketing of the company’s innovative DNA sequencing products, which are used in research laboratories worldwide. 454 Life Sciences was acquired by Roche Diagnostics in 2007.
Mr. McLeod earned his B.S. Magna Cum Laud with a dual major in economics and engineering and applied science from Yale University and his M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology.
Dan Wagner is responsible for evaluating healthcare/life science investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Dan has led or assisted with Connecticut Innovations’ investments in Affomix (acquired by Illumina), AlloMek Therapeutics (acquired by Pasithea Therapeutics (Nasdaq: KTTA), Arvinas (NASDAQ: ARVN), AxioMx (acquired by Abcam), Azitra (NYSE: AZTR) ,Biohaven Pharmaceuticals (NYSE: BHVN), Biorez (acquired by CONMED), Cara Therapeutics (NASDAQ: CARA), CyVek (acquired by Bio-Techne), HistoRx (acquired by Genoptix/Novartis), IsoPlexis (NASDAQ: ISO), Kleo Pharmaceuticals (acquired by Biohaven Pharmaceuticals), Medically Home Group (acquired by Mayo Clinic and Kaiser Permanente), Melinta Therapeutics, formerly Rib-X (NASDAQ: MLNT), and Rallybio (NASDAQ: RLYB).
Dan contributes to CII’s expertise in biotech with more than 10 years in the industry. He was previously at CuraGen Corporation, a successful former CI portfolio company.
Kevin has over 20 years of successful commercial experience in market-leading and start-up life science research companies. Prior to joining Enrich Biosystems Inc., Kevin was a leading contributor in the commercial adoption of innovative solutions from Leica Microsystems, Perkin Elmer, ForteBio and others. His true motivation is making an impact on the success of his customers and drug development in general by advocating for the adoption of new technologies, especially Enrich Biosystems’ TROVO platform, that provide new and unique capabilities for more efficient and successful therapeutic discoveries.
In his free time, Kevin enjoys a variety of activities including sports, cooking, traveling and hiking with his family in Southbury, CT.
Xueqi obtained his undergraduate and graduate training major in Biophysics at Tsinghua University in Beijing, where he studied macromolecule atomic structures and functions using X-crystallography technology. He did postdoc training in Yale University in Connecticut, where he researched on biological molecule functionalities using cutting-edge Cryo-Electron Microscopy. He also obtained a master’s degree major in Computer Science at University of New Haven, where he was motivated to pioneer in empowering biological and medical science using innovative interdisciplinary tools. He is enthusiastic about Enrich Biosystem’s unique science and technologies to accelerate therapeutic discoveries and human health care.
Qi has a broad background in biology, physics and engineering, with specific training and expertise in key research areas for this application. In graduate school , he accomplished several challenging projects in virology, human DNA repair field, participated in a number of collaborations and further consolidate my skills in protein structure, computational biology and molecular biology. After joining AxioMx/Abcam Inc, he led and finished a number of clone screening platforms and several data-intensive rational library construction projects. He also authored and oversaw several NIH funded projects for new methods of developing function modulating antibodies against GPCR and enzymes. After Abcam, he co-founded Enrich to develop advanced phenotypical screening and evolution platforms. With the collaborated effort from biology and engineering, he constructed a number of functional cell libraries and invented devices to observe and capture functional phenotypes on crucial cells in immune oncology.
As Co-founder and Chief Executive Officer, Dong leads Enrich Biosystems in its mission to develop a highly integrated high-throughput cell imaging/analysis/capture platform and unleash its microfluidics-free technology to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Over the span of his 20 years career, Dong held various leadership positions in research, product, operation, and business development in various private and public life science companies, including Abcam, AxioMx, Illumina, and Affomix. Dong received both B.S. and M.S. degrees from University of Science and Technology Beijing and completed postgraduate training in Structural Biology at Cellular and Molecular Physiology Department of Yale University.
During his personal time, Dong enjoys playing soccer, traveling, and most importantly, spending quality time with his family.
